story of the week
Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neuro-Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter
Neuro-oncology 2022 May 02;[EPub Ahead of Print], M Lim, M Weller, A Idbaih, J Steinbach, G Finocchiaro, RR Raval, G Ansstas, J Baehring, JW Taylor, J Honnorat, K Petrecca, F De Vos, A Wick, A Sumrall, S Sahebjam, IK Mellinghoff, M Kinoshita, M Roberts, R Slepetis, D Warad, D Leung, M Lee, DA Reardon, A OmuroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.